Over the past 3 years, the exports had a slightly negative dynamics in monetary terms. However, the situation became more favorable in 2016, when the total exports of finished medicinal products amounted to $305 million, which was less than 1% lower than in the previous year, while in 2015 the fall was 6%. In physical terms, the exports grew by 6.3% in 2016.
In 2016, 48.5% of total exports went to Ukraine (32.3%) and Uzbekistan (16.2%). The significant increase in the exports to Ukraine is primarily due to large-scale shipments of medicines to the territory of Donbass and Lugansk region. Traditionally, the leading suppliers to Ukraine are importers Nizhpharm Ukraine JSC (16.7%) and Metropolia LLC (15.7%).
Despite the decrease in volume of deliveries to Uzbekistan (down by more than 22%), this country retained the second position in the ranking. In 2016, 22% of all exports to Uzbekistan were made of medicines manufactured by Biotech and Materia Medica. The imports of medicines to Tajikistan have been affected by the legislative changes in the country. For example, in 2016, the imports from the Russian Federation dropped by 9%.
A significant increase in the exports to Lithuania (up by more than 40%) deserves special attention. It is due to increased deliveries of Russian-made antibacterials for systemic use.
The policy of the Russian government aimed at bringing the manufacturing of medicinal products in line with international standards contributed to the start of expansion into European markets and in Latin America.